Introduction
Purinergic receptor-7 (P2X7R), primarily expressed on lymphocytes, senses adenosine 5′-triphosphate (ATP) (1) released extracellularly during cell damage (2, 3) and has been shown to regulate T cell activation (4) (5) (6) . In particular, P2X7R signaling favors T helper 1 (Th1) and Th17 generation and differentiation (7) (8) (9) , which are involved in alloimmune responses and allograft rejection (10) (11) (12) (13) (14) . Our group has indeed demonstrated a major role for the extracellular ATP/P2X7R axis in regulating Th1/Th17 differentiation during cardiac allograft rejection (15) (16) (17) . Interestingly, the opposite T cell immune-polarizing role has been recently described for NOD-like receptor P3 (NLRP3) (18) , with NLRP3 acting as a DNA-binding transcriptional factor to promote an IL-4-mediated Th2 program in CD4 + T cells (19) . The interaction between NLRP3 and P2X7R has been described in various cells, but not in T lymphocytes (20, 21) . We hypothesize that a P2X7R/ NLRP3 pathway within T cells controls Th cell fate, which may be dysregulated by mutation of P2X7R, thus driving excessive Th17 generation, particularly upon allostimulation due to abrogation of the NLRP3-mediated Th2 program. Interestingly, a single-nucleotide polymorphism (SNP), rs3751143 (p.Glu496Ala/c.1513A>C), located in exon 13 of P2X7R, targets the intracellular C-terminal portion of P2X7R. This mutation is relatively frequent -with 25% of the general population heterozygous and 2% homozygousand results in loss of function of P2X7R (22) (23) (24) (25) (26) (27) (28) (29) . In this study, we have explored the existence of a P2X7R/NLRP3 pathway within T cells that controls Th cell fate and the effect of a P2X7R loss-offunction mutation on this pathway, on Th cell fate, and on clinical outcomes in a large cohort of cardiac-transplanted patients.
Results

A P2X7R/NLRP3 pathway exists in CD4
+ T cells. Given that an interaction between P2X7R and NLRP3 has been documented in other cell types (i.e., microglial cells, leukemic cells) (20, 21) , we initially explored whether a similar association exists in T cells, particularly in human CD4 + T cells. We observed that NLRP3 and P2X7R reciprocally immunoprecipitated in CD4 + T cells isolated from peripheral blood mononuclear cells (PBMCs) obtained from human subjects ( Figure 1A and Supplemental Figure 1A ; supplemental material and complete unedited blots available online with this article; https://doi.org/10.1172/JCI94524DS1). We then conPurinergic receptor-7 (P2X7R) signaling controls Th17 and Th1 generation/differentiation, while NOD-like receptor P3 (NLRP3) acts as a Th2 transcriptional factor. Here, we demonstrated the existence of a P2X7R/NLRP3 pathway in T cells that is dysregulated by a P2X7R intracellular region loss-of-function mutation, leading to NLRP3 displacement and to excessive Th17 generation due to abrogation of the NLRP3-mediated Th2 program. This ultimately resulted in poor outcomes in cardiac-transplanted patients carrying the mutant allele, who showed abnormal Th17 generation. Transient NLRP3 silencing in nonmutant T cells or overexpression in mutant T cells normalized the Th profile. Interestingly, IL-17 blockade reduced Th17 skewing of human T cells in vitro and abrogated the severe allograft vasculopathy and abnormal Th17 generation observed in preclinical models in which P2X7R was genetically deleted. This P2X7R intracellular region mutation thus impaired the modulatory effects of P2X7R on NLRP3 expression and function in T cells and led to NLRP3 dysregulation and Th17 skewing, delineating a high-risk group of cardiac-transplanted patients who may benefit from personalized therapy.
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T cells were challenged in vitro with BzATP and downregulated when P2X7R inhibitor (CE-224,535) was added ( Figure 1 , J-M), thus supporting the existence of a P2X7R/NLRP3 pathway that controls human CD4 + T cell fate. We finally demonstrated the absence of a reciprocal link between P2X7R and NLRP3 within human CD4 + T cells by showing that NLRP3 blockade using siRNA silencing or NLRP3 inhibitor (CP-456773) did not alter P2X7R expression (Supplemental Figure 1, B-D) .
The P2X7R rs3751143 loss-of-function mutation affects intracellular P2X7R function. The availability of a large cohort of cardiactransplanted patient samples and data sets provided by 3 inter- (Figure 1, D-F) . Moreover, we confirmed that in CD4 + T cells, the activation of P2X7R signaling with BzATP is associated with an increase in P2X7R and NLRP3 colocalization ( Figure 1I ). Further analysis of NLRP3 downstream signaling revealed that the expres- + T cells activated with BzATP and treated with the P2X7R inhibitor CE-224,535. Experiments were run in triplicate (n = 5). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; 1-way ANOVA with Bonferroni's post hoc test or Student's t test. mRNA expression was normalized to β-actin (ACTB). jci.org
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the effect of the P2X7R mutation, we first conducted transcriptome profiling of immune-relevant genes in CD4 + T cells (Supplemental Table 3 ). Interestingly, this profiling revealed a reduction in NLRP3 and P2X7R mRNA expression in CD4 + T cells obtained from patients carrying the mutant P2X7R allele as compared with noncarrier patients (Figure 2D ), suggesting that the interaction between P2X7R and NLRP3 is altered in the presence of the P2X7R mutation. Quantitative reverse transcriptase PCR (qRT-PCR), flow cytometric, and protein expression analysis confirmed the downregulation of NLRP3 mRNA ( Figure 2E ) and protein (Figure 2 , F and G) in CD4 + T cells, particularly in naive but not in effector or memory T cell subsets (Supplemental Figure  2F) , and in CD4 + P2X7R + cells, obtained from patients carrying the mutant allele ( Figure 2, H and I) . The near absence of NLRP3 and its reduced colocalization with P2X7R in CD4 + carrier T cells were also confirmed with immunofluorescence studies ( Figure  2 , J and K, and Supplemental Figure 2G ). Confocal imaging and subcellular fractionation studies demonstrated that while NLRP3 is present in the cytoplasm in CD4 + T cells of noncarrier patients, it appears confined to the cell membrane of CD4 + T cells in patients carrying the mutant allele ( Figure 2 , K and L), suggesting that the P2X7R mutation may prevent NLRP3 translocation to the nucleus. Indeed, chromatin immunoprecipitation (ChIP) experiments revealed that DNA encoding IL-4 and IRF4, the transcription factor that in conjunction with NLRP3 transactivates the IL-4 promoter, was clearly bound to NLRP3 precipitated from CD4 + T cells of noncarrier patients, while it was slightly detectably bound to NLRP3 precipitated from CD4 + T cells of carrier patients (Figure 2 , M and N), confirming NLRP3 displacement and absence of its binding to DNA in the promoter regions of Th2-related genes in mutant CD4 + T cells. However, NLRP3 translocation could not entirely explain the reduced expression of NLRP3 observed in CD4 + T cells of carrier patients. We thus studied the ubiquitinmediated degradation of NLRP3 and demonstrated that it was accelerated in CD4 + carrier T cells as compared with noncarrier cells, and that the addition of the proteasome and ubiquitination inhibitor MG132 to cultured CD4
+ T cells appears to restore NLRP3 expression ( Figure 2O ). NLRP3 is thus not only displaced but also is prone to degradation in mutant CD4 + T cells. This may also apply to NLRP3 mRNA, which is decreased in CD4 + T cells of carriers, as a result of reduced mRNA half-life and accelerated mRNA degradation (Supplemental Figure 2H) . We further observed reduced levels of the phosphorylated intracellular factor STAT5, a transcriptional regulator of NLRP3, in CD4 + T cells of carriers as compared with noncarriers (Supplemental Figure  2I) , which most likely plays a role in reducing NLRP3 mRNA transcription. Finally, we confirmed that epigenetic regulation of NLRP3 DNA via NLRP3 promoter methylation was not altered in carriers as compared with noncarriers (Supplemental Figure  2J) , and that P2X7R did not directly bind to DNA of NLRP3 or NLRP3-related genes (i.e., STAT5, NF-κB, MyD88, IL-10) in carrier/noncarrier CD4 + T cells (data not shown) to modulate NLRP3 mRNA transcription.
The dysregulated P2X7R/NLRP3 pathway is associated with altered Th cell fate. We next confirmed a role for P2X7R/NLRP3 dysregulation in driving Th cell fate during immune activation. In an ex vivo T cell polarization assay in which CD4 + T cells were national independent studies (the CTOT-05, the NIT-Bergamo, and the AIRT-Bologna) and the recently established crucial role of P2X7R signaling in alloimmune response activation led us to explore the hypothesis that a mutation in P2X7R may alter T cell phenotype/function and ultimately affect cardiac transplantation outcomes, by disrupting the regulatory effect of P2X7R on NLRP3 expression and function. Intriguingly, the already described P2X7R loss-of-function mutation rs3751143 is quite frequent in its homozygous mutated state (nearly 2% in the general population, and 7% in cardiactransplanted patients), and it mainly targets the C-terminal intracellular domain (24, 25) . We thus performed bioinformatic protein sequence analysis of P2X7R and determined that the intracellular region is predicted to be composed of significant secondary structure elements, and that mutation of Glu496 likely disrupts some of the molecular functions of P2X7R (Figure 2A ). We then identified carriers of the mutation by genotyping the 413 cardiac-transplanted patients enrolled in the 3 aforementioned studies (Supplemental Table 1 ). First, we observed that P2X7R and NLRP3 reciprocally immunoprecipitate in CD4 + T cells of carriers, in both the heterozygous and the homozygous state (Supplemental Figure 1A) . Next, we demonstrated that total protein expression of P2X7R was higher in carrier as compared with noncarrier CD4 + T cells ( Figure 2B ), but that surface expression was similar (Supplemental Figure 1, Figure 1G ).
To further explore any functional alterations in P2X7R, CD4 + T cells were isolated from collected blood samples (Supplemental Table 2 ), and a significant reduction in the BzATP-stimulated intracellular calcium peak (Supplemental Figure 1H ) was observed in carriers of the mutation as compared with noncarriers, while influx of larger cations such as ethidium + and YO-PRO-1 ++ was only slightly affected (Supplemental Figure 1, I and J). To further characterize the effects of the P2X7R mutation on other cell functions, we analyzed the intracellular bacterial killing capability of macrophages at different time points (24 and 48 hours) and demonstrated that this function was not altered in carriers as compared with noncarriers (Supplemental Figure 1K) . A reduction in mRNA expression of P2X7R was also observed in CD4 + T cells of carriers as compared with noncarriers ( Figure 2C ), but this was paralleled by a relative increase in mRNA expression of other P2X receptors, such as P2X1R and P2X4R (Supplemental Figure 2, A and B) . In line with this observation, delayed ubiquitination/degradation of the P2X7R protein was evident in CD4 + carrier T cells as compared with noncarriers and resulted in protein accumulation within the cells (Supplemental Figure 2C ). This likely leads to reduced P2X7R mRNA levels in CD4 + T cells of carriers. Other potential mechanisms such as methylation of the P2X7R promoter or altered P2X7R mRNA half-life were shown not to be associated with a decrease in P2X7R mRNA levels (Supplemental Figure 2, D nificantly reduced in carrier patients as compared with noncarriers ( Table 1 ). This skewing was paralleled by an increase in the percentage of Th1/Th17 cells in the circulation (Figure 3 , B and C, and Table 1 ) as well as a decrease in Th2 cells in carrier patients (Table 1) . We further proved the shifted balance toward Th17 by differentiated by anti-CD3-Ig/anti-CD28-Ig stimulation in the appropriate cytokine milieu for Th1, Th2, or Th17 cells, a skewing to the Th17 -and to a lesser extent Th1 -lineage was evident in patients carrying the mutant allele as compared with noncarriers ( Figure 3A and Table 1) , and the generation of Th2 cells was sig- + T cells treated with the ubiquitin/protease inhibitor MG132 (n = 3). Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; Student's t test or 2-way ANOVA with Bonferroni's post hoc test. jci.org
Th17 cytokines IL-17, IL-6, and IL-22 in the culture supernatants of these cells ( Figure 3F ). Finally, Th17-polarized cells of carriers also showed higher production of the proinflammatory cytokines IFN-γ and TNF-α, and reduced release of the antiinflammatory cytokine IL-1ra ( Figure 3F and Supplemental Figure 2L ), while no difference was found with regard to IL-10 ( Figure 3F ). Moreover, given the association of Th17 skewing in immune events occurring after transplantation, including cardiac allograft vasculopathy, with the development of an autoimmune response against vimentin (30, detecting increased peripheral IL-17 levels in the plasma and in the supernatants of unstimulated CD4 + T cells of carrier as compared with noncarrier patients matched for clinical characteristics (Figure 3 , D and E). In order to better characterize the Th17 shift in carrier cells, we demonstrated higher expression of the Th17-related markers CCR6, CCR10, and IL-22 -the latter to a lesser degree -in differentiated Th17 cells of carriers as compared with noncarriers by flow cytometric analysis ( Figure 3F and Supplemental Figure 2K ), which was confirmed by increased production of the ) were evident as well in carrier as compared with noncarrier patients (Table  1) , thus suggesting an increased effector-type immune response. The P2X7R intracellular domain mutation may thus directly alter T cell phenotype. Transient genetic overexpression and downregulation of NLRP3 were then used to ultimately confirm the reciprocal link between the dysregulated P2X7R/NLRP3 pathway and altered Th cell fate. Silencing of NLRP3 in CD4 + T cells of noncarrier patients reduced mRNA expression of Th2-related factors ( Figure 3 , G and H, and Supplemental Figure 3A ) and was associated with a concomitant increase in the Th17-related factor RORc upon stimulation (Supplemental Figure 3B) . Unlike the silencing of NLRP3 (Figure 3 To finally further establish whether our findings regarding P2X7R/NLRP3 dysregulation in T cells are limited to transplant patients or are also relevant to the general population, we performed the aforementioned experiments in nontransplanted patients (Supplemental Table 4 ). Indeed, reduced expression of NLRP3 in CD4 + T cells (Supplemental Figure 4A ), P2X7R/ NLRP3 displacement (Supplemental Figure 4B) , reduction in Th2 cells, and Th17 skewing in the periphery (Supplemental Figure 4 , C and D) and during Th2/Th17 generation in vitro (Supplemental Figure 4 , E and F) were all observed in nontransplanted carriers compared with noncarriers as well.
Anti-IL-17 neutralizing antibody abrogates the deleterious effects of P2X7R loss of function. With the goal of developing a personalized therapy for carriers of the mutation, we tested whether treatment with an anti-IL-17 neutralizing antibody would be effective in abrogating the altered CD4 + T cell phenotype in carriers of the P2X7R mutation. Reduced Th17 skewing was observed when anti-IL-17 neutralizing antibody, but not immunosuppressive drugs currently used in transplantation (i.e., rapamycin and cyclosporine) or a Th1 inhibitor, was added to an in vitro Th17 generation assay in which CD4 + T cells obtained from carriers were used ( Figure 3N ). We then tested the effect of an anti-IL-17 neutralizing antibody in a preclinical model of cardiac transplantation. Surprisingly,
P2X7R
-/-C57BL/6 recipients of bm12 hearts (an established MHC class II-mismatched model of chronic allograft vasculopathy) experienced increased allograft loss as compared with wild-type C57BL/6 recipients ( Figure 4A -/-mouse model by demonstrating that NLRP3 expression is lower within CD4 + T cells than in C57BL/6 mice ( Figure 4O ), and we observed a decreased Th2 response, particularly with respect to IL-4, upon in vitro and in vivo allostimulation (Figure 4 , G, J, P, and Q). We acknowledge that the murine model is different from cardiac-transplanted patients, who are heavily immunosuppressed and receive a fully MHC-mismatched cardiac allograft. However, these murine data largely parallel our observations in carrier patients (Supplemental Table 5 ), thus suggesting that an anti-IL-17-based treatment may help to prevent or delay the onset of immune events in cardiactransplanted patients carrying the P2X7R mutation.
The dysregulated P2X7R/NLRP3 pathway is associated with poor outcomes in cardiac-transplanted patients. To finally assess the clinical impact of the dysregulated P2X7R/NLRP3 pathway in cardiactransplanted patients bearing the P2X7R mutant allele, we studied clinical and immunological outcomes of 413 cardiac-transplanted patients enrolled in the CTOT-05, NIT-Bergamo, and AIRT-Bologna international studies. We first confirmed that the frequency of the P2X7R mutation in the heterozygous condition was similar in the 3 cohorts and in the National Heart, Lung, and Blood Institute (NHLBI) Grand Opportunity (GO) Exome Sequencing Project (ESP) cohort, while the percentage of patients in the homozygous mutant condition was lower in the ESP cohort as compared with what was observed in cardiac-transplanted patients (nearly 7.5%) (Supplemental Table 6 ). We next analyzed an early outcome in the CTOT-05 cohort by examining what proportion showed an incremental change greater than 5 mm in intracoronary ultrasonography-measured coronary artery maximal intimal thickness (MIT), which defines rapidly progressive cardiac allograft vasculopathy following heart transplantation. A significant increase in MIT was observed in 13 of 40 carriers (32.5%), and in 9 of 62 noncarrier patients (14.5%; P = 0.04; Figure 5A ). Carrying the mutant allele was thus associated with an increased odds ratio (OR) for developing an incremental change in coronary artery MIT within the first year after transplant (OR = 2.83, CI 1.1-7.4, P = 0.04; Table 1 ), and this association was confirmed after controlling for the most relevant modifying factors (age, sex, pretransplant cardiomyopathy, and immunosuppressive therapy) as shown in Supplemental Table 7 . We then studied in the NIT-Bergamo cohort the number of clinically assessed and/or biopsy-proven acute rejection episodes, observing an increased frequency of events in carrier as compared with noncarrier patients (10.4 ± 0.5 vs. 8.7 ± 0.4, P = 0.01; Figure 5B ) within the first year after transplantation, with a higher proportion of patients experiencing more than 3 acute rejection events per year (66/70 [94%] in carriers vs. 92/111 [83%] in noncarrier patients, P = 0.03; Table 1 ). Carrying the mutant allele was thus associated with an increased OR for developing a higher number of acute rejection episodes within the first year after transplant (OR = 3.40, CI 1.1-10.5, P = 0.04; Table 1 ), which was confirmed after controlling for other factors potentially involved (age, sex, pretransplant 
3). (P) Number of IL-4-producing cells (ELISPOT) in P2X7R
-/-and B6 mice upon allostimulation (n = 3). (Q) Serum IL-4 level (Luminex), measured in B6 and P2X7R -/-cardiactransplanted mice (n = 5). Samples were run in duplicate (Luminex) and in triplicate (ELISPOT). Bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001; log-rank (Mantel-Cox) test (A), Wilcoxon's and Student's t test (2 groups), 1-way ANOVA with Bonferroni's post hoc test (3 groups). jci.org Volume 128 Number 8 August 2018 In the NIT-Bergamo cohort, the OR was calculated based on the requirement of medical intervention for acute rejection episodes with a frequency of greater or less than 3 episodes. *P < 0.05; **P < 0.01. Supplemental Tables 7-9 Our results were also confirmed in a group of nontransplanted patients, among whom reduced expression of NLRP3 in CD4 + T cells, displacement of P2X7R/NLRP3, reduction in Th2 cells, and Th17 skewing (both in the periphery and during Th2/Th17 generation in vitro) were observed in carriers as compared with noncarriers. Further studies are certainly needed to confirm this observation in a larger population, but these data suggest that carriers of the mutant P2X7R allele may represent a population of patients with a fragile immune system at risk of developing a hyper-Th17 syndrome in response to various immune stimulations (e.g., infections, inflammation, or tissue damage).
Some limitations of our study should be noted. Firstly, the bm12 into C57BL/6 heart transplantation murine model does not faithfully replicate the condition of cardiac transplantation in humans, given minor HLA mismatching, a reduced degree of transplant atherosclerosis, and the lack of a concomitant immunosuppression therapy in this model. Secondly, with respect to human studies, a larger cohort would have certainly provided greater statistical power to the association between P2X7R mutation and immune disorders. Thirdly and finally, the complexity of the clinical assessment in our study, which included multiple outcomes evaluated at different time points, as well as the heterogeneity in clinical practice among study centers, may reduce the strength of this analysis. Future studies would benefit from improvement upon these limitations, with the rate of immune events in patients with the P2X7R mutation as a primary endpoint.
In summary, the P2X7R/NLRP3 complex maintains a physiological NLRP3-mediated Th2 program, while intracellular mutation of P2X7R induces NLRP3 displacement in T cells, causing Th17 skewing and resulting in poor allograft outcome ( Figure 5 , E and F). Our study demonstrates, for the first time to our knowledge, the existence of a novel mechanism controlling T cell fate and delineates a group of cardiac-transplanted patients with Th17 skewing and with worse clinical and immunological outcomes, as well as identifies a population who may benefit from selective targeted therapy.
Methods
A detailed description of the methods used in this study is provided in the Supplemental Methods.
Genotyping of P2X7R rs3751143 DNA was extracted from anticoagulated peripheral blood samples obtained from each patient using the Qiagen QIAamp DNA Blood Mini Kit (51104, Qiagen). Genotypes were determined using an Applied Biosystems TaqMan Human SNP Genotyping Assay (4351376, Thermo Fisher Scientific) for rs3751143 in accordance with the manufacturer's protocol. cardiomyopathy, and immunosuppressive therapy; Supplemental Table 8 ). Finally, we analyzed the long-term impact of the mutation and observed in the AIRT-Bologna cohort an increased frequency of major adverse cardiac events (MACEs) within 10 years after transplantation in 22 of 39 carriers (56.4%) compared with 27 of 91 noncarrier patients (29.7%; P = 0.005; Figure 5C ). Carrying the mutant allele was thus associated with an increased OR for developing MACEs after transplantation also in the long term (OR = 3.07, CI 1.4-6.6, P = 0.006; Table 1 ), which was confirmed after adjustment for clinically relevant factors (age, sex, pretransplant cardiomyopathy, and immunosuppressive therapy), as reported in Supplemental Table 9 . Despite the heterogeneity in practice among study centers (e.g., suboptimal standardization of clinically relevant outcomes, decision algorithm for immunosuppressive and/or other treatments), our findings collectively demonstrate that the dysregulated P2X7R/NLRP3 pathway in cardiac-transplanted patients bearing the P2X7R mutant allele is associated with an increased risk of developing poor outcomes such as rapidly progressive cardiac allograft vasculopathy and higher frequency of acute rejection episodes and long-term MACEs following transplantation ( Figure 5D ).
Discussion
This study offers a novel understanding of the mechanisms that may control Th cell fate by suggesting that P2X7R exerts a regulatory effect on NLRP3 within CD4 + T cells, which is required to maintain NLRP3 in the proper intracytoplasmic/nuclear position and in an operative mode, thus facilitating its nuclear action (i.e., interaction with the IL-4 promoter and IRF4) and Th2 commitment. Moreover, in our study a group of patients at high risk for immune events related to dysregulation of the P2X7R/NLRP3 pathway and who may require personalized therapy has been identified. We demonstrated that mutation of the P2X7R intracellular region affects Th cell fate, favoring skewing toward Th17 generation, leading to a more pronounced effector/inflammatory phenotype and thus exposing patients to the risk of allograft loss. Given the importance of the Th17 response in allograft rejection (32) , understanding the mechanism whereby the mutation of P2X7R favors Th17 skewing is highly clinically relevant. Interestingly, we observed that this mutation in the P2X7R intracellular region directly favors NLRP3 displacement and redirects NLRP3 to the cell membrane compartment. This prevents the nuclear transcriptional and DNA binding activity of NLRP3, as well as results in its accelerated ubiquitination and rapid proteolysis, thus abrogating NLRP3-mediated Th2 differentiation (19) and inducing Th17 skewing. While ubiquitination is a key mechanism in regulating NLRP3 activation within cells that helps to maintain its transcriptional activity (33, 34) , we discovered that proper function of the P2X7R/NLRP3 pathway appears to be crucial in rescuing NLRP3 from ubiquitin-mediated degradation and in preserving its function within T cells. A genetic addback experiment confirmed the link between the dysregulated P2X7R/NLRP3 pathway and altered Th skewing. enyi Biotec) according to the manufacturer's instructions. The purity of the isolated CD4 + T cell population routinely exceeded 95%.
Flow cytometry and intracellular cytokine staining of human cells. Primary antibodies included anti-human CD45 (560178), CD4
(561030), CD8 (560774), CD25 (560503), CCR7 (557648), CD127 (557938), IFN-γ (554702), IL-4 (554484), IL-10 (554498) (all BD Biosciences); IL-17 (12-7178-41), CD45RO (MHD45R005) (both Thermo Fisher Scientific); and CD3 (300330, BioLegend). FITC-conjugated anti-mouse P2X7R (APR-008-F) was purchased from Alomone Labs. Alexa Fluor 700-conjugated anti-human NLRP3 (IC7578N) was purchased from R&D Systems. Purified anti-human NLRP3 (IC7578G) and Alexa Fluor 488-conjugated anti-rabbit NLRP3 (IC7578G) were purchased from R&D Systems and BD Biosciences, respectively. Resting cells were activated with PMA (5 ng/ml; 13-144, Sigma-Aldrich) and ionomycin (500 ng/ml; 13909, Sigma-Aldrich) for 3 hours; then brefeldin A (2 μM; B7651, Sigma-Aldrich) was added. Cells were harvested in FACS tubes and placed on ice. Cells were then washed with FACSFlow (342003, BD Biosciences) and processed for intracellular cytokine staining with saponin 0.5% (47036, Sigma-Aldrich) and formaldehyde 2% (F8775) for fixation and permeabilization. Anti-phospho-STAT5-PE (pY694, clone 47, 562077, BD Biosciences) was used to assess intracellular phospho-STAT5 expression per the manufacturer's instructions.
Human Th cell differentiation. CD4 + T cells isolated from recovered
PBMCs were stimulated with anti-CD3-Ig (1 μg/ml; HMCD0300, Life Technologies), anti-CD28-Ig (2 μg/ml; CD2800, Life Technologies), and rIL-2 (50 U/ml; 202-IL, R&D Systems). For Th1 differentiation, rIL-12 (2.5 ng/ml; 219-IL, R&D Systems) and anti-IL-4 (5 μg/ml; 204-IL, R&D Systems) were added. For Th2 differentiation, rIL-4 (12.5 ng/ ml; 504-RL, R&D Systems), anti-IFN-γ (5 μg/ml; AHC4032, Invitrogen), and anti-IL-10 (5 μg/ml; 501505, BioLegend) were added. For Th17 differentiation, rIL-1β (1290-IL, R&D Systems), rIL-6 (206-IL, R&D Systems), and rTGF-β (240-B, R&D Systems) (final concentration 10 ng/ml) were added. After 4 days, cells were harvested and stained for FACS analysis. Th1 cells were defined as producing IFN-γ, Th2 cells were defined as producing either IL-4 or IL-10, and Th17 cells were defined as producing IL-17. For detailed Th17 characterization, the expression of CCR6 (563922, BD Biosciences), CCR10 (56769, BD Biosciences), and IL-22 (12-7229-41, Thermo Fisher Scientific) was also assessed. Human peripheral IL-17 levels. Levels of IL-17 were measured using an IL-17 Human Quantikine ELISA kit (D1700, R&D Systems) per the manufacturer's instructions. Plasma samples from cardiac-transplanted patients (Supplemental Table 2 ) and from nontransplanted patients were diluted per kit protocol and analyzed by an ELISA plate reader according to the manufacturer's instructions.
Luminex cytokine measurement. Levels of cytokines were assessed in culture supernatants of CD4 + T cells using the Bio-Plex Pro human cytokine 17-plex panel (M5000031YV, Bio-Rad) according to the manufacturer's protocol. The Hu Th17 IL-22 set (171BA008M, BioRad) was used to detect IL-22.
Intracellular calcium response of human CD4 + T cells. Isolated
PBMCs were thawed, and recovered CD4 + T cells were purified as described above. CD4 + T cells were then cultured in RPMI 1640 (Life Technologies) supplemented with 10% FBS, 2 mM l-glutamine, and 100 U/ml penicillin (Life Technologies). After 48 hours, cells were resuspended at 1 × 10 7 cells/ml and incubated in 2.5 μM fluo-3AM
Study cohorts and clinical endpoints
In order to study the effects of rs3751143, we have established a large international cohort of 747 cardiac-transplanted patients, which includes the US-based Clinical Trials in Organ Transplantation-05 (CTOT-05) cohort, the Northern Italian Transplant (NIT, Bergamo, Italy) group, and the Inter-Regional Transplant Association (AIRT, Bologna, Italy). Genotype and immunological and clinical outcomes were evaluated in all patients (Supplemental Table 1 ). The CTOT-05, an observational study designed to understand the natural history of cardiac allograft vasculopathy, comprises 200 cardiactransplanted patients enrolled in the United States from June 2007 to July 2011. Coronary artery vasculopathy, as defined by a change in MIT of ≥0.5 mm through intracoronary ultrasonography (IVUS) (35) between study entry and 12 months, was assessed. Of the 200 patients enrolled in the CTOT-05, 148 were genotyped, and IVUS was performed in 102 patients.
The NIT cohort consists of 187 patients who underwent cardiac transplantation at Divisione Cardiovascolare, Ospedali Riuniti in Bergamo, Italy, from 1985 to 2012. Acute rejection episodes, either clinically assessed and/or proven by biopsy, were recorded over a period of 12 months after transplant. Patients were grouped according to number of episodes (either higher or lower than 3) that required medical intervention and/or hospitalization within the first year. Of the 187 patients enrolled, 187 were genotyped, and acute rejection episodes were observed in 181 patients.
The AIRT cohort consists of 360 cardiac-transplanted patients followed within the Heart Failure and Heart Transplant Program at the Department of Experimental Diagnostic and Specialty Medicine, S. Orsola Hospital in Bologna, Italy, between 1985 and 2013. Clinical outcome was defined by the occurrence of major adverse cardiac events (MACEs), which included nonfatal myocardial infarction, coronary revascularization, and hospitalization for graft failure, over a long-term follow-up (10 years) from the time of transplantation (36) . Of the 360 patients enrolled, 359 were genotyped, and data on MACEs for follow-up of at least 10 years from the time of transplantation were available in 130 patients.
Patients carrying the mutant allele for P2X7R in either the homozygous or the heterozygous state were included in the analysis of clinical outcome. Blood was collected according to the following timeline: 1.1 ± 0.4 years of follow-up in the CTOT-05 cohort; 5 ± 1.2 years of follow-up in the NIT-Bergamo cohort; and 15 ± 0.8 years of follow-up in the AIRTBologna cohort. Fifty healthy volunteers matched for age and sex were chosen as controls (Supplemental Table 4 ). The study was approved by the ethics committee of each participating institution.
Immunological studies PBMC isolation and CD4
+ T cell purification. PBMCs were isolated from 10-ml blood samples collected from cardiac-transplanted patients (Supplemental Table 2 ) and from nontransplanted patients 
Immunofluorescence
Immunofluorescence analysis of CD4 + T cells was performed using the following primary antibodies: rat anti-NLRP3 (MAB7578, R&D Systems) with a 1:100 dilution and rabbit anti-P2X7 (P8232, SigmaAldrich) at a 1:50 dilution. Secondary antibodies were as follows: donkey anti-rat-TRITC (712-025-150, Jackson ImmunoResearch) and donkey anti-rabbit-FITC (711-095-152, Jackson ImmunoResearch), at a 1:50 dilution. Analysis of immunofluorescence and collection of images were conducted using a confocal system (TCS SP5 laser scanning confocal, Leica). , respectively) (37). Membrane integrity was assessed using the BD Horizon Fixable Viability Stain 510 kit (564406, BD Biosciences) to exclude dead cells. The mean fluorescence intensity of relative cation uptake was determined using FlowJo software (version 8, Tree Star).
Interventional in vitro studies
Anti-IL-17 (10 μg/ml; MAB3171-100, R&D Systems), CE-224,535 (50 μM; provided by Pfizer), RMT1-10 (100 μg/ml; BE0133, BioXCell), rapamycin (6 ng/ml; R8781, Sigma-Aldrich), and cyclosporine (100 ng/ml; PHR1092, Sigma-Aldrich) were used in vitro in a Th17 assay using concentrations already tested and described or according to blood levels used in drug monitoring (17, (38) (39) (40) (41) (42) . Cells were stimulated with BzATP (50 μM) for 24 hours to activate P2X7R in vitro as previously described (20) . The effect of inflammasome activation was tested by addition of the inflammasome inhibitor CP-456773 (200 μM; PZ0280, Sigma-Aldrich) to short-term BzATP (5 mM) stimulation for 1 hour in vitro as already described (43) .
Transcriptome profiling
Total RNA was extracted from CD4 + T cells isolated from PBMCs obtained from each group of patients, using the RNeasy Mini Kit (74104, Qiagen) with on-column DNase I digestion. Next, 3 μg total RNA from each sample was reverse-transcribed using the RT2 First Strand kit (330401, SABiosciences). The Human Inflammasome RT2 Profiler PCR Array (PAHS-097Z, Qiagen) platform was used to quantitatively measure the expression of a panel of genes using SYBR Green-based real-time PCR (Supplemental Table 3 ). minutes and at baseline and 30 and 90 minutes, respectively, in order to evaluate ubiquitin-mediated degradation. The ubiquitin inhibitor MG132 (M8699, Sigma-Aldrich) was added in order to block ubiquitin-mediated degradation, and NLRP3 or P2X7R was quantified at the same time points described above (44, 45) .
Bioinformatic analysis and protein modeling
The P2X7R intracellular sequence (from residues 360-595) was submitted to I-TASSER algorithms for 3D protein structure prediction as previously described (46), producing 10 models, the best of which had a normalized Z score of 1.17.
Bacterial killing CD14 + cells were isolated from PBMCs of carrier and noncarrier patients using CD14 microbeads (130-050-201, Miltenyi), followed by cell culture over 7 days in RPMI 1640 supplemented with 10% FBS, 25 mM HEPES, M-CSF (50 ng/ml), penicillin (100 U/ml), and streptomycin (100 mg/ml). Cells were then coincubated with equal numbers of E. coli for 24 and 48 hours. Lysates obtained were plated onto agar plates, and viable bacteria were counted (CFU) (47, 48) .
ELISPOT autoimmune assay
An ELISPOT assay (552138, BD Biosciences) was used to measure IFN-γ production by responder cells when restimulated with vimentin peptide (2105-VI, R&D Systems) (31) . Vimentin peptide (20 μg/ ml), anti-CD3-and anti-CD28-Ig (1 μg/ml and 2 μg/ml, respectively; CD0300 and CD2800, Life Technologies), tetanus toxoid mixture (1 μl; Diftavax, Sanofi Pasteur), or IA-2 (100 μg/ml; Pierce Biotechnology Inc.) was used to stimulate 1 × 10 5 responder PBMCs obtained from carrier and noncarrier patients for 48 hours. Spots were counted using an ImmunoSpot analyzer (CTL Europe GmbH) as previously described (15) .
Statistics
Continuous variables are presented as means and standard errors, and categorical variables are presented as proportions. We used independent sample t tests to compare continuous variables and χ 2 test/ Fisher's exact test to compare categorical variables. For multiple comparisons, 1-way or 2-way ANOVA followed by Bonferroni's post hoc test between the group of interest and all other groups was used. All multivariable analyses were adjusted for age and sex. Univariable and multivariable logistic regression methods were used to model the relationships between risk factors and outcomes of interest. Two-tailed P values less than 0.05 were considered statistically significant.
Study approval
Human and animal studies were approved by the appropriate institutional review board(s) of Boston Children's Hospital (Boston, Massachusetts, USA); Ospedale S. Orsola Malpighi (Bologna, Italy); and Ospedali Riuniti di Bergamo (Bergamo, Italy). Written informed consent was received from participants prior to inclusion in the study. 
Author contributions
Subcellular localization
Subcellular fractionation of CD4 + T cells was performed using the Qiagen Qproteome Cell Compartment kit (37502, Qiagen), which enables the sequential isolation of proteins associated with the cytosol, membranes, nucleus, and cytoskeleton from cell lysates. Briefly, cells were isolated as previously described and then pelleted. Cytosolic extraction buffer was added, and the respective fraction was isolated by centrifugation. Addition of membrane extraction buffer was used to obtain the membrane fraction per the manufacturer's instructions. Expression of NLRP3 and of P2X7R was further assessed in each fraction using an ELISA kit as described above. NLRP3 or P2X7R in each cell fraction was reported as picograms per microgram of total NLRP3 or P2X7R, and data were expressed as percentage of NLRP3 or of P2X7R detected in each compartment.
Assessment of NLRP3 DNA binding using modified ChIP
We performed chromatin immunoprecipitation (ChIP) using an Agarose ChIP Kit (26156, Thermo Fisher Scientific). Briefly, CD4 + T cells were isolated as above, and protein-DNA complexes were stabilized and then extracted. In vivo cross-linking was achieved with formaldehyde. To lyse, extract, and solubilize the cross-linked complexes, the Thermo Fisher Scientific Chromatin Prep Module was used (included in the kit), thus reducing contamination of the chromatinbound DNA from other cellular compartments and enriching samples for NLRP3. Once chromatin was digested, immunoprecipitation of NLRP3 was performed as described above (see "Immunoprecipitation"). To analyze protein-binding sequences, genomic DNA was sheared into small pieces with enzymatic digestion per the manufacturer's instructions. After proteinase digestion and cross-link reversal, DNA was purified, and expression of genes of interest (IRF4, IL-4) was assessed using a TaqMan Copy Number Assay (Hs0201197cn, Hs00092447cn, Applied Biosystems). Expression of genes was normalized to that of total non-immunoprecipitated DNA extracted from the same number of cells.
Ubiquitin-mediated culturing experiments CD4 + T cells isolated from carrier and noncarrier PBMCs were cultured as previously described in the presence of an inhibitor of protein synthesis, cycloheximide (C4859-1ML, Sigma-Aldrich), and NLRP3 and P2X7R protein was quantified at baseline and 30, 60, 90, and 120 jci. MI collected data and samples. SDP performed protein structure analysis. DC performed immunostaining and histology analysis. GV, RCS, RA, AC, PSH, BEE, GVZ, FF, MHS, and FG coordinated sample collection, designed research, and edited the paper. PF designed research, and wrote and edited the paper.
